Biotech company Cidara Therapeutics is developing drug-Fc conjugate immunotherapies for serious diseases. Janssen Pharmaceuticals, a Johnson & Johnson subsidiary, has given Cidara a go-ahead for CD388 (JNJ-0953), a universal prevention solution for influenza A and B.

Guangzhou Gloria Biosciences has announced that Zimberelimab injection (YuTuo®, GLS-010), has received marketing approval from the China NMPA.

SpliSense declared the successful completion of a Phase 1 clinical trial for SPL84.

Verismo Therapeutics, a clinical-stage company specializing in CAR-T therapies, has initiated the dosing of the first patient in their STAR-101 clinical trial.

Viking Therapeutics, Inc. has recently commenced a Phase 2 clinical evaluation of VK2735.

Atamyo Therapeutics proclaimed that the FDA has given the green light for its ATA-100 IND application to advance into a Phase 1b/2b clinical study.

VBI Vaccines Inc. publicized that its strategic HBV collaborator, Brii Biosciences announced preliminary group-level unmasked 36-week data from a mid-term examination of a randomly assigned, placebo-controlled, and double-concealed Phase 2 investigation of BRII-179 (VBI-2601).

Johnson's Janssen Pharmaceutical Companies have disclosed encouraging preliminary findings from the tri-modality Phase 3 MARIPOSA-2 trial.

Genentech, part of the Roche Group, has revealed that the FDA has accepted to their BLA for crovalimab, an exploratory, newly-developed anti-C5 recycling monoclonal antibody.

Beam Therapeutics Inc., a firm in the biotechnology sector focusing on the creation of exact genetic treatments via base editing, declared that the first patient received BEAM-201 treatment.

Eledon Pharmaceuticals, Inc. revealed that it has administered the initial dose to the first participant in the BESTOW Phase 2 study.

uniQureN.V.,announces that their AMT-260 Gene Therapy candidate, developed for the treatment of Refractory Mesial Temporal Lobe Epilepsy, has received approval for the Investigational New Drug Application from the FDA.